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Background: Social cognitionmay be critical to the impoverished social functioning seen in seriousmental illness.
However, although social-cognitive deﬁcits are consistently demonstrated in schizophrenia spectrum disorders
(SSD), studies in bipolar disorder (BD) have produced inconsistent results. This inconsistency may relate to
symptomproﬁles of patients studied, particularly the presence or absence of psychotic features. Thus, we examined
social cognition in bipolar disorderwith psychotic features (BD+)versuswithout psychotic features (BD−) relative
to SSD and controls.
Methods:A sample of 537 SSD patients, 85 BD+patients, 37 BD− patients, and 309 controlswere administered the
MATRICS Consensus Cognitive Battery, including a social cognition measure, the managing emotions branch of the
Mayer–Salovey–Caruso Emotional Intelligence Test (MSCEIT). Analyses of covariance compared MSCEIT perfor-
mance between diagnostic groups while controlling for race, psychotropic medication status, and neurocognition.
Results: SSD but not BD− or BD+ patients showed signiﬁcant MSCEIT deﬁcits relative to controls.
Conclusions:MSCEIT deﬁcitswere found in SSDbut not BD−or BD+, suggesting that social cognitionmay represent
an underlying difference between SSD and BD. However, variance in MSCEIT performance among BD patients may
also suggest latent BD subgroups characterized by social-cognitive deﬁcits. Findings can help inform future investi-
gations into how social cognition and social brain development differ between SSD and BD.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bipolar disorder (BD) patients suffer from multiple functional im-
pairments including impoverished social functioning (Cannon et al.,
1997; Pope et al., 2007), which have prompted investigations into
social-cognitive deﬁcits in BD. Social cognition is a multidimensional
construct that includes identifying affect others display, inferring others'
mental states, attributing meanings to others' actions, reading others'
social cues, applying a working knowledge of social rules to socially re-
ciprocate in kind, and managing one's own emotional responses to
maintain interpersonal relationships (Green et al., 2008a; Green andgrants from the National Insti-
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Inc. This is an open access article unHoran, 2010; Pinkham et al., 2014). Understanding bipolar patients'
social-cognitive deﬁcits may help illuminate mechanisms underlying
impaired social competence in BD, which may help inform interven-
tions to improve psychosocial functioning.
Yet to date, results of social cognition studies in BD have been incon-
sistent. While some studies have found social-cognitive deﬁcits (Bora
et al., 2005; Bozikas et al., 2006; David et al., 2014; Harmer et al.,
2002; Hoertnagl et al., 2011; Inoue et al., 2004; Kerr et al., 2003; Lembke
and Ketter, 2002; Martino et al., 2008, 2011; Soeiro-de-Souza et al.,
2012a,b; Wolf et al., 2010), others have found mixed results with pre-
served aspects alongside deﬁcits (Addington and Addington, 1998;
Getz et al., 2003; McKinnon et al., 2010; Montag et al., 2010; Olley
et al., 2005; Schaefer et al., 2010; Shamay-Tsoory et al., 2009; Summers
et al., 2006; Vederman et al., 2012), and others have found no deﬁcits
relative to controls (Barrera et al., 2013; Lee et al., 2013; Van Rheenen
and Rossell, 2014; Vaskinn et al., 2007; Venn et al., 2004). Social-
cognitive differences have also been found between BD−I and BD−II,
or between manic or depressive phases of BD (Derntl et al., 2009;
Gray et al., 2006). As a result, the nature of social-cognitive deﬁcits in
BD remains inconclusive.
In contrast, schizophrenia spectrum disorders (SSD) have consis-
tently shown substantial deﬁcits in both social cognition andder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2010; Fiszdon et al., 2013; Green et al., 2012; Kee et al., 2009; Kern
et al., 2011; Kimhy et al., 2012; Thompson et al., 2012; Torgalsbøen
et al., 2014; Tso et al., 2010). Findings suggest that such deﬁcits remain
stable across phases of psychosis (Green et al., 2012) and are linked to
SSD patients' quality of life and community, work, and social function-
ing (Fiszdon et al., 2013; Horan et al., 2012; Kee et al., 2009; Maat
et al., 2012; Shamsi et al., 2011; Shi et al., 2013; Tso et al., 2010). More-
over, results suggest that social cognition is more strongly linked with
community functioning than neurocognition (Fett et al., 2011), and
mediates the relationship between neurocognition and functional out-
comes (Bell et al., 2009; Schmidt et al., 2011).
Recently, it has been suggested that inconsistent past ﬁndings in BD
may reﬂect the impact of co-occurring psychotic symptoms on social-
cognitive performance (Thaler et al., 2013a,b), especially considering
~60% of bipolar patients will also experience psychotic symptoms at
some point during their lifetimes (Dunayevich and Keck, 2000). Specif-
ically, bipolar patients with psychotic features (BD+) have shown
greater social-cognitive deﬁcits than those without psychotic features
(BD−) (Thaler et al., 2013a,b). Although we previously reported
(Burdick et al., 2011) no signiﬁcant effect of a history of psychotic fea-
tures in a bipolar sample substantially overlapping with the sample
used in our current analyses, our prior work did not control for
neurocognition and did not directly compare against SSD, which may
have limited these past ﬁndings. In addition, although a study by Lee
et al. (2013) also found no effect of a history of psychotic features on
their BD patients' social-cognitive deﬁcits, only 15 of their 68 patients
(~22%) had a history of psychotic features, and thus this sample may
have been underpowered to detect group differences. Therefore, it is
possible that social-cognitive deﬁcits may present in BD+ but not
BD−when directly compared to SSD and controls.
Examining social cognition across SSD, BD+, BD−, and controls may
illuminatewhether a history of psychotic features impairs social cognition
in BD relative to SSD. Findings could help identify BD patients in need of
social-cognitive interventions and help elucidate if social cognition repre-
sents an underlying difference between BD and SSD. Thus, we comparedTable 1
Study group and subsample demographics and clinical characteristics.




Total sample N 309 37 85
– BD 1 (N = 17) BD 2 (N = 20) BD 1 (
Age: mean (SD) 40.52 (16.34) 41.24 (10.06) 40.61
% Female 55.99% 59.46%` 55.29
% Caucasian 52.75% 54.05% 56.47
Substance disorder history 0% 16.22% 27.05
Anticonvulsant use 0 18 32
Antidepressant use 0 15 19
Mood stabilizer use 0 11 21
Antiparkinsonian use 0 4 10
Anxiolytic use 0 5 8
Antipsychotic use 0 23 54
Sedative/Hypnotic use 0 4 6
Stimulant use 0 1 0
N of subsample with BPRS – 21 60
– BD 1 (N = 11) BD 2 (N = 10) BD 1 (
Brief psychiatric rating
scale (BPRS): Mean (SD)
– – –
Thinking Disturbance – 3.86 (1.11) 4.23 (
Withdrawal/Retardation – 3.05 (1.07) 2.75 (
Hostile/Suspiciousness – 4.86 (1.68) 4.45 (
Anxious/Depression – 6.48 (2.89) 5.02 (
Activation – 4.86 (2.01) 4.47 (
BPRS Total Score – 29.10 (5.80) 27.07social-cognitive performance differences among these diagnoses while
controlling for neurocognition and psychotropic medication status.2. Methods
2.1. Participants
Our sample consisted of 968 participants, with 537 SSD patients
(447 schizophrenia and 90 schizoaffective disorder patients), 85 BD+
patients, 37 BD− patients, and 309 controls. For full demographics
and clinical characteristics, see Table 1. All participants gave written in-
formed consent to protocols approved by the Institutional ReviewBoard
of the North Shore-Long Island Jewish Health System (NSLIJ). Controls
were recruited using newspaper and Internet advertisements, posted
ﬂyers, and personal referrals. Patientswere referred from the outpatient
and inpatient psychiatric departments of Zucker Hillside Hospital
(ZHH), part of NSLIJ. Controls were excluded if diagnosed with past or
present Axis-I disorders, had substance abuse within the past month,
or had a history of learning disability, neurological disorder, or CNS trau-
ma. Patients were excluded if they had a history of learning disability,
neurological disorder, or CNS trauma.2.2. Clinical assessments
2.2.1. Diagnostic assessment
Controls were administered the Structured Clinical Interview for
the DSM-IV, non-patient edition (SCID-I/NP; First et al., 2001a) and
patients were administered the patient edition (SCID-I/P; First
et al., 2001b) by Ph.D. or Master's level psychometricians. Controls'
SCIDs were compiled into narrative case summaries and no Axis-I
pathology was determined by consensus of two senior ZHH faculty.
Patients' SCIDs were supplemented by available records and compiled
into narrative case summaries and diagnoses were determined by
consensus of three senior ZHH faculty.r disorder (BD) with
otic features
SSD spectrum disorder Statistic p
537
N = 85) BD 2 (N = 0) – – –
(11.43) 43.26 (10.20) F(3,967) = 3.62 p b .05
% 26.82% χ2(3,967) = 86.01 p b .001
% 37.80% χ2(6,967) = 39.85 p b .001










N = 60) BD 2 (N = 0) – – –
– – –
2.04) 6.16 (3.04) F(2,572) = 17.15 p b .001
1.28) 3.66 (1.86) F(2,572) = 7.86 p b .001
1.78) 4.99 (2.06) F(2,572) = 1.92 ns
2.40) 4.85 (2.22) F(2,572) = 5.22 p b .01
1.92) 4.47 (1.86) F(2,572) = 0.43 ns
(7.58) 31.14 (7.44) F(2,572) = 8.58 p b .001
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Patients' clinical symptoms were assessed by trained Master's level
psychometricians using the Brief Psychiatric Rating Scale (BPRS; Overall
and Gorham, 1962), a semi-structured clinical interview assessing 18
symptoms within the past week.
2.4. Cognitive assessment
To assess neurocognition, all participants were administered the
MATRICS Consensus Cognitive Battery (MCCB), which consists of 10
measures assessing seven domains: (1) processing speed, measured
by the symbol coding subtest of the Brief Assessment of Cognition in
Schizophrenia (BACS symbol coding; Keefe et al., 2004), the Trail Making
Test: Part A (Trails-A; Army Individual Test Battery, 1944), and Category
Fluency: Animal Naming (animal naming; Spreen and Strauss, 1998);
(2) attention/vigilance, measured by the Continuous Performance
Test—Identical Pairs (CPT-IP; Cornblatt et al., 1988); (3) workingmemo-
ry, measured by the spatial span subtest of theWechsler Memory Scale,
Third Edition (WMS-III spatial span;Wechsler, 1997) and Letter–Number
Span (LNS; Gold et al., 1997); (4) verbal learning, measured by the
Hopkins Verbal Learning Test—Revised (HVLT-R; Brandt and Benedict,
2001); (5) visual learning, measured by the Brief Visuospatial Memory
Test—Revised (BVMT-R; Benedict, 1997); (6) reasoning and problem
solving, measured by the Neuropsychological Assessment Batterymazes
subtest (NAB Mazes; Stern and White, 2003); and (7) social cognition,
measured by the managing emotions branch of the Mayer–Salovey
Emotional Intelligence Test (MSCEIT; Mayer, 2002).
The MSCEIT has evidenced robust psychometric properties, with
demonstrated applicability in BD (Burdick et al., 2011; Lee et al.,
2013), SSD (Green et al., 2008b), and controls (Kern et al., 2008), good
internal consistency (Eack et al., 2010;Mayer et al., 2003), good sensitivity
to deﬁcits in SSD and BD (Burdick et al., 2011; Kee et al., 2009; Van
Rheenen and Rossell, 2014), and good validity in SSD, as SSD patients'
MSCEIT performance has been signiﬁcantly linked to social functioning
(Shamsi et al., 2011) and residential independence (Lin et al., 2012), and
has been improved by social-cognitive interventions (Eack et al., 2007).
2.5. MCCB scoring
While published normswere available for eachMCCB domain (Kern
et al., 2008), our sample of healthy control participants was better de-
mographically matched to our bipolar and schizophrenia spectrum pa-
tient samples, as the Kern et al. (2008) data were not stratiﬁed by
race. Speciﬁcally, the Kern et al. (2008) healthy control sample
consisted of 76% Caucasian participants, whereas our healthy control
participants consisted of 52.75% Caucasian participants, which was bet-
ter matched to our BD−, BD+, and SSD patients (being 54.05%, 56.47%
and 37.8% Caucasian, respectively). Thus, we chose to calculate Z-scores
using means and standard deviations derived from our healthy control
data, which provided improved demographic matching on race. Using
our healthy control data, age and sex were regressed out of eachTable 2
MCCB domain scores by diagnostic group standardized using MCCB normative data.




Mean (SD) Mean (SD)
Processing speed 48.63 (10.43) 40.19 (10.69)
Attention vigilance 46.97 (10.66) 39.76 (12.91)
Working memory 44.82 (10.44) 37.57 (13.04)
Verbal learning 42.59 (8.28) 39.38 (8.96)
Visual learning 41.57 (11.74) 34.84 (12.27)
Reasoning/problem solving 45.68 (10.38) 42.22 (8.72)
Social cognition 49.06 (10.98) 47.46 (11.34)
Overall composite score 42.68 (10.68) 34.00 (11.60)MCCB raw score to produce standardized residuals that were then
transformed to Z-scores. A neurocognition score was calculated by
averaging across the 6 nonsocial MCCB domains. Next, MSCEIT and
neurocognition Z-scores were inspected for outliers over ±3 standard
deviations from the mean. There were no outliers for neurocognition,
but 4 extreme low MSCEIT scores were identiﬁed and excluded (i.e.
one BD+, two SSD, and one control case). Resulting age- and sex-
corrected Z-scores consisted of (1) an MSCEIT Z-score and (2) a
neurocognition Z-score. Both were normally distributed (K–S = 0.83
and 1.16 for neurocognition and MSCEIT, respectively, both p's N 0.05).
Since we chose to derive MCCB scores using our own healthy control
data, we have provided T-score means and standard deviations for all
our diagnostic groups using the MCCB published norms in Table 2 for
descriptive purposes and for ease of comparison to previous work on
the MCCB.
2.6. Data analysis
Diagnostic groups were ﬁrst compared on demographics using chi-
squares for sex and race and analysis of variance for age. Demographic
variables that signiﬁcantly differed between groups were corrected for
or included as covariates.
To investigate whether MSCEIT deﬁcits would be demonstrated in
all BD patients relative to SSD and controls, we ﬁrst compared SSD pa-
tients, all BD patients, and controls using analysis of covariance
(ANCOVA) controlling for race, neurocognition, and psychotropic med-
ication status. Next, to examine the impact of psychosis history on
MSCEIT performance in BD, we conducted a follow-up ANCOVA com-
paring SSD, BD+, BD−, and control groups, controlling for race,
neurocognition, and psychotropic medication status.
Race consisted of a categorical variable with Caucasian, African-
American, and other minority group. Psychotropic medication status
consisted of 8 dummy-coded variables that each assessed the presence
or absence of anticonvulsant, antidepressant, mood stabilizer,
antiparkinsonian, anxiolytic, antipsychotic, sedative, or stimulant use.
All patients were on at least one form of psychotropic medication and
thus all 8 variables were included in all ANCOVAs. No controls had any
history of psychotropic medication use.
3. Results
Preliminary analyses revealed the sex and race distributions signiﬁ-
cantly differed between diagnostic categories, with fewer females and
more minorities in the SSD group compared to other groups (sex:
χ2(3,967) = 86.01, p b 0.001; race: χ2(6,967) = 39.85, p b 0.001).
Age also signiﬁcantly differed between groups, with SSD patients slightly
older than controls but no signiﬁcant age differences between any other
groups (F (3,967)=3.62, p b 0.05). Thus, we corrected allMCCB subtests
for age and sex and controlled for race in all ANCOVAs.
Results from the ﬁrst ANCOVA found signiﬁcant MSCEIT differences
between SSD patients, all BD patients, and controls (F (2, 964)= 24.85,
p b 0.001), controlling for race, neurocognition, and psychotropicout
= 37)
Bipolar disorder with
psychotic features (N = 85)
SSD spectrum disorder
(N = 537)
Mean (SD) Mean (SD)
38.12 (9.05) 29.80 (14.03)
36.89 (12.86) 32.13 (12.36)
37.47 (10.51) 31.76 (13.16)
37.76 (7.29) 34.50 (7.36)
35.80 (12.46) 30.31 (12.23)
41.01 (8.75) 37.49 (8.33)
44.08 (13.50) 35.67 (12.05)
31.67 (11.35) 22.55 (12.13)
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found no signiﬁcant MSCEIT differences between BD patients and con-
trols, but rather only signiﬁcant differences between SSD patients and
controls and between BD and SSD patients. Signiﬁcant covariates in-
cluded neurocognition (F (1,964) = 92.29, p b 0.001) and antidepres-
sant use (F (1,964) = 11.59, p b 0.001), while all other covariates
were non-signiﬁcant (all p's N 0.05).
Results from the second ANCOVA also found signiﬁcant MSCEIT dif-
ferences between the BD+, BD−, SSD, and control groups (F (3,964)=
16.83, p b 0.001), controlling for race, neurocognition, and psychotropic
medication status. Follow-up pairwise comparisons using Fisher's LSD
found no signiﬁcant MSCEIT differences between BD+, BD−, and con-
trols. Rather, the only signiﬁcant difference was between SSD and all
other groups. Signiﬁcant covariates similarly included neurocognition
(F (1,964) = 91.99, p b 0.001) and antidepressant use (F (1,964) =
11.02, p b 0.001), while all other covariates were non-signiﬁcant (all
p's N 0.05). For a plot of MSCEITmeans across all four diagnostic groups,
see Fig. 1.4. Discussion
This study's primary aimwas to examine social cognition across SSD,
BD+, and BD− patients relative to controls. In particular, given ~60% of
BD patients also experience psychotic symptoms at some point during
their lifetimes, often during acute phases of illness (Dunayevich and
Keck, 2000), and recent studies have found BD+ patients to show sig-
niﬁcant social-cognitive deﬁcits (Thaler et al., 2013a,b), our study
aimed to elucidate whether BD+ patients would show impaired
MSCEIT performance relative to BD− patients and controls, as well as
whether deﬁcits would be consistent with SSD patients. However, in
contrast to recent studies showing social-cognitive deﬁcits in BD+
(Thaler et al., 2013a,b), but consistent with past work showing no
social-cognitive deﬁcits in BD (Barrera et al., 2013; Lee et al., 2013;
Vaskinn et al., 2007; Venn et al., 2004), our analyses found signiﬁcantFig. 1. Social cognition performance across diagnostic categories. Note: Error bars repre-
sent ±1 standard error. MSCEIT = the managing emotions branch of the Mayer–
Salovey–Caruso Emotional Intelligence Test, the social cognition measure of the MATRICS
Consensus Cognitive Battery (MCCB). All MCCB scores including the MSCEIT are age- and
sex-corrected, and the comparison of MSCEIT performance across diagnostic groupings
controlled for race and neurocognition.MSCEIT deﬁcits in SSD but not BD+ or BD− patients relative to con-
trols. These results suggest that social cognition may represent a key
underlying difference between SSD and BD.
Another possible explanation is that social-cognitive impairments of
BD patients are more heterogeneous than those found in SSD. Consis-
tentwith this, our sample of BD+ and BD− patients both had larger es-
timates of standard error on the MSCEIT than the other diagnostic
groups, which might indicate the presence of latent bipolar subgroups
that differ in their social-cognitive performance. To investigate this pos-
sibility, we examined a histogram of MSCEIT Z-scores for easily visible
subgroups within our bipolar sample (both BD+ and BD−). The distri-
bution was unimodal and normally distributed (K–S = 0.83, p N 0.05),
which was not suggestive of latent bipolar subgroups. It is still possible
that there are latent subgroups of BD patients with different levels of
social-cognitive performance, but that properly identifying these sub-
groups requires the use of more advanced statistical techniques such
as hierarchical cluster analysis. Although outside the scope of the present
study, future studies should use larger bipolar cohorts andmore sophisti-
cated analytic methods to investigate this possibility of latent subgroups
of bipolar patients with differential social-cognitive performance.
An important limitation of our study was the lack of multiple mea-
sures of social cognition and the limited scope of the MSCEIT as social
cognition measure. Speciﬁcally, the MSCEIT has evidenced some weak-
nesses in its ability to fully tap into the multifaceted construct of social
cognition (Burdick et al., 2011), and Lee et al. (2013) used a battery
that includedmultiple aspects of social cognition. Unfortunately, multi-
ple social-cognitivemeasureswere not available for our study. However,
one beneﬁt of the MSCEIT is that it is particularly well-suited to our
study's transdiagnostic focus. Ceiling effects are a key problem for
many social-cognitive measures, with controls often performing at
over 90% accuracy (Dodell-Feder et al., 2013). As a result, past studies
may have lacked sensitivity to subtle social-cognitive differences be-
tween BD patients and controls. In addition, the factor structure of social
cognition in populations suffering from psychotic symptoms is still
largely unknown and many measures have inadequate psychometric
properties (Green et al., 2008a). In contrast, the MSCEIT was both
developed for non-clinical populations and was the chosen consensus
metric of the MCCB for studying serious psychiatric disorders (Kern
et al., 2008; Nuechterlein et al., 2008), Thus, while limited in scope, the
MSCEIT is apt for studying social-cognitive deﬁcits across SSD and BD
subtypes and for verifying past evidence of social-cognitive deﬁcits in
BD+ patients (Lee et al., 2013; Thaler et al., 2013a,b). Nevertheless,
social cognition remains amultifaceted construct that is not yet fully un-
derstood, and it is possible that BD patients may show deﬁcits in social-
cognitive domains not fully captured by the MSCEIT. Future studies are
needed to develop and validate standardized, multifaceted social-
cognitive batteries sensitive to subtle differences across clinical and
nonclinical populations. Large-scale studies are also needed to assess
performance on these batteries across all SSD and BD subtypes.
Our ﬁndings were also limited by differences in demographic distri-
butions between study groups. Speciﬁcally, our SSD group was slightly
older and had fewer females and more minorities compared to our
other groups. However, we controlled for race in all analyses and
MCCB subtests were all age- and sex-corrected, which helped attenuate
any demographic differences between groups.
Although it may be argued that differences in symptom severity of
our patient groups contributed to our ﬁndings, we ran a follow-up
ANCOVA controlling for the total symptom severity score of the BPRS
in a subsample of 570 patients who had been administered the BPRS
(i.e., 21 BD−, 59 BD+, and 490 SSD patients). Results conﬁrmed our
ﬁndings, with no signiﬁcantMSCEIT deﬁcits in BD− or BD+ but signif-
icant deﬁcits in SSD relative to controls. Nevertheless, BPRS ratingswere
unfortunately not available for every patient and thus the possibility
clinical symptoms impacted our ﬁndings cannot be completely ruled
out. Moreover, differences in symptoms are often accompanied by dif-
ferences in medication status. However, our analyses controlled for 8
6 G.C. Nitzburg et al. / Schizophrenia Research: Cognition 2 (2015) 2–7classes of psychotropic medications and although including these 8 co-
variates had the potential to adversely affect statistical power, our large
sample sizewithstood the inclusion of these covariateswhilemaintaining
excellent power (1− β= 0.9).
In summary, our evidence supports past work showing social-
cognitive deﬁcits in SSD but not BD+ or BD− relative to controls
(Barrera et al., 2013; Lee et al., 2013; Vaskinn et al., 2007; Venn et al.,
2004). While these data suggest that social cognition may represent
an underlying difference between SSD and BD, the large variance in
social-cognitive performance among the bipolar groups is also sugges-
tive of heterogeneity in performance and may indicate a latent bipolar
subgroup characterized by social-cognitive deﬁcits. Results highlight
the importance of developing standardized social-cognitive batteries
for use across BD and SSD and emphasize the need for future work on
social brain development in clinical populations.
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